Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02192931 · ClinicalTrials.gov registry record · Phase 4
A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users
A Phase 4 study, sponsored by Perry Renshaw.
- Completed
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
NCT02192931 is a Phase 4 study that has completed, run by Perry Renshaw. The registered enrollment target is 65 participants.
The verdict
NCT02192931, a Phase 4 study, has completed, sponsored by Perry Renshaw.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
Study Summary
Methamphetamine (MA) addiction is a public health concern that causes substantial harm to individual users, and imposes an economic burden in the U.S. totaling up to $48.3 billion annually. This study proposes to address a critical aspect of this problem: the lack of any proven, FDA-approved pharmacological treatments for MA users. The proposal combines an intervention designed to improve energy metabolism in the brain, and a neuroimaging technique capable of measuring the neurochemicals that represent cerebral bioenergetic function. The study will replicate and extend a key neuroimaging finding from the investigators recent MA studies: that MA users have decreased phosphocreatine (PCr) levels in the brain, compared to healthy volunteers. Phosphocreatine is the substrate reservoir for the creatine kinase reaction, which reversibly converts PCr into adenosine triphosphate (ATP), the brain's major energy supply, and creatine. Neuronal energy demands are met through a shift in reaction equilibrium, which is designed to maintain the concentration of ATP constant. Research results from the investigators recent study also showed that female MA users have lower brain PCr levels compared to male users. These findings join the converging lines of evidence that MA use is associated with mitochondrial dysfunction, i.e. deficient energy metabolism, in the brain. Frequently, MA users also experience depression, as well as cognitive deficits. Interestingly, both of these entities are also linked to mitochondrial dysfunction in the brain. The long-term goal of this research program is to define the alterations in brain chemistry that underlie MA use disorders, and to utilize translational magnetic resonance spectroscopy (MRS) neuroimaging to identify rational brain-based treatment targets. Once a hypothesis-driven intervention is identified, MRS can then be further employed in treatment studies, to verify that "target engagement" is achieved. The specific aims of this proposal ar
Interventions
- DRUG Creatine monohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2014-09 |
| Est. Completion | 2023-01-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02192931
The ClinicalTrials.gov registry entry for NCT02192931 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Perry Renshaw, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Creatine monohydrate is the first listed.
NCT02192931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02192931 about?
NCT02192931 is a clinical study titled "A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users". Methamphetamine (MA) addiction is a public health concern that causes substantial harm to individual users, and imposes an economic burden in the U.S. totaling up to $48.3 billion annually. This study proposes to address a critical aspect of this problem: the lack of any proven, FDA-approved pharmac...
What is the current status of trial NCT02192931?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2014-09. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT02192931?
The interventions under investigation include: Creatine monohydrate (DRUG).
Who is sponsoring clinical trial NCT02192931?
This trial is sponsored by Perry Renshaw, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.